=> d l1
L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1 22 16
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 17:03:56 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4760 TO ITERATE

100.0% PROCESSED 4760 ITERATIONS 53 ANSWERS
SEARCH TIME: 00.00.01

L3 53 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 188.28 188.50

FILE 'CAPLUS' ENTERED AT 17:04:02 ON 03 DEC 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Dec 2009 VOL 151 ISS 23
FILE LAST UPDATED: 2 Dec 2009 (20091202/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2009

CAplus now includes complete International Patent Classification (IPC)

reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

```
=> s l3
L4           6 L3

=> d bib abs 1-6

L4   ANSWER 1 OF 6  CAPLUS  COPYRIGHT 2009 ACS on STN
AN   2009:1230178  CAPLUS
DN   151:448246
TI   New carbazole derivatives, especially 9-substituted
     4-heteroaryl-9H-carbazoles, compositions containing them and their use as
     HSP90 inhibitors for treating cancer
IN   Alasia, Marcel; Bertin, Luc; Cerval, Victor; Halley, Frank; Mailliet,
     Patrick; Mendez Perez, Maria; Minoux, Herve; Ruxer, Jean-Marie
PA   Sanofi-Aventis, Fr.
SO   PCT Int. Appl., 321pp.
     CODEN: PIXXD2
DT   Patent
LA   French
FAN.CNT 2
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2009122034        A2    20091008    WO 2009-FR267          20090313
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
             ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     FR 2928645           A1    20090918    FR 2008-1394           20080314
PRAI FR 2008-1394         A     20080314
OS   MARPAT 151:448246
GI
```



I



II

AB The invention is related to the preparation of carbazoles I [Het = (un)substituted aromatic or partially unsatd. (dihydro or tetrahydro) mono or bicyclic 5-11 membered heterocycle containing 1-4 heteroatoms selected from N, O or S; R = 3-amino-4-(aminocarbonyl)phenyl, 3-amino-1H-indazol-6-yl, 3-amino-1,2-benzoxazol-6-yl, etc.], and their tautomers and stereoisomers, and their mineral and organic acid and base addition salts, and their prodrugs, and to their use as inhibitors of the activity of the protein chaperone Hsp90, and more particularly their use as inhibitors of the catalytic ATPase activity of Hsp90 for treating cancer and other proliferative disorders. Thus, reacting Me 9H-carbazole-4-carboxylate (preparation given) with 2-bromo-4-fluorobenzonitrile, followed by amination of the bromide with trans-4-aminocyclohexanol, saponification of the Me ester, amidation of the acid with 4-fluoro-o-phenylenediamine, cyclization in the presence of AcOH at reflux and conversion of the nitrile to amide with an aqueous solution of H2O2 gave II. Selected I had IC50 in the range of 1 μM to 10 μM for the inhibition of Hsp82 ATPase activity.

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2008:548314 CAPLUS
DN 148:538082
TI Preparation of phenylamino-substituted piperidine compounds as NPY5 receptor regulators
IN Garcia-Lopez, Monica; Mas-Prio, Josep; Torrens-Jover, Antonio
PA Laboratorios Del Dr. Esteve S.A., Spain
SO PCT Int. Appl., 90pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008052769	A1	20080508	WO 2007-EP9465	20071031

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1918281 A1 20080507 EP 2006-384017 20061102
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

EP 2099752 A1 20090916 EP 2007-819497 20071031
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR

PRAI EP 2006-384017 A 20061102
WO 2007-EP9465 W 20071031

OS MARPAT 148:538082

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X, Y = H, halo, nitro, etc.; R1-R3 = H, halo, aliphatic radical, etc.; R5 = H, aliphatic radical or -A-CO-NR10R11; R6-R9 = H, aliphatic radical, cyano, etc.; A = -CHR18 or -CHR18-CH2-; R10 = H or aliphatic radical; R11 = aliphatic radical, cycloaliph. radical, aryl radical, etc.; R18 = H or aliphatic radical] or stereoisomers (preferably enantiomers or diastereomers), racemates, mixts. of at least two of stereoisomers (preferably enantiomers or diastereomers, in any mixing ratio), salts (preferably physiol. acceptable salts), or solvates thereof were prepared Thus, a multi-step synthesis of compound II [R = OH; Z = -CO-], starting from 3-aminofluoren-9-one, was given. In Neuropeptide Y5 (NPY5) binding assays, the IC50 value of compound II [R = H; Z = -N(Et)-] (III) was 23.7 nM. Compds. I are claimed useful for the treatment of obesity, anorexia, etc. Pharmaceutical composition comprising compound III is disclosed.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:636147 CAPLUS
DN 143:205792
TI A preliminary study of the metabolic stability of a series of benzoxazinone derivatives as potent neuropeptide Y5 antagonists
AU Dordal, Alberto; Lipkin, Mike; Macritchie, Jackie; Mas, Josep; Port, Adriana; Rose, Sally; Salgado, Leonardo; Savic, Vladimir; Schmidt, Wolfgang; Serafini, Maria Teresa; Spearing, William; Torrens, Antoni; Yeste, Sandra
CS BioFocus Discovery Limited, Saffron Walden, CB10 1XL, UK
SO Bioorganic & Medicinal Chemistry Letters (2005), 15(16), 3679-3684
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier B.V.
DT Journal
LA English
AB The metabolic stability of benzoxazinone derivs., a potent series of NPY

Y5 antagonists, has been investigated. This study resulted in the identification of the structural moieties prone to metabolic transformations and which strongly influenced the in vitro half-life. This provides opportunities to optimize the structure of this new class of NPY Y5 antagonists.

OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:136598 CAPLUS
DN 142:240323
TI Active substance combination comprising a compound with NPY receptor affinity and a compound with 5-HT6 receptor affinity
IN Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Codony Soler, Xavier; Merce Vidal, Ramon; Aurelio Castrillo Perez, Jose; Frigola Constansa, Jordi; Buschmann, Helmut-Heinrich
PA Laboratorios del Esteve S. A., Spain
SO PCT Int. Appl., 427 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005014045	A1	20050217	WO 2004-EP8514	20040729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	ES 2228268	A1	20050401	ES 2003-1815	20030730
	ES 2228268	B1	20060701		
	AU 2004262488	A1	20050217	AU 2004-262488	20040729
	CA 2534099	A1	20050217	CA 2004-2534099	20040729
	EP 1660131	A1	20060531	EP 2004-741321	20040729
	EP 1660131	B1	20090624		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	AT 434446	T	20090715	AT 2004-741321	20040729
	ES 2328485	T3	20091113	ES 2004-741321	20040729
	IN 2005DN06119	A	20080711	IN 2005-DN6119	20051228
	MX 2006001230	A	20060515	MX 2006-1230	20060130
	US 20070009597	A1	20070111	US 2006-566402	20060705
PRAI	ES 2003-1815	A	20030730		
	WO 2004-EP8514	W	20040729		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OS CASREACT 142:240323; MARPAT 142:240323
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The present invention relates to an active substance combination comprising at least one compound I [R1-R4 = H, halo, alkyl, etc.; R5 = H, alkyl, (un)saturated cycloalkyl; R6-R9 = H, alkyl, (un)saturated cycloalkyl, etc.;
A = CHR18, CHR18CH2; B = alkyl, (un)saturated cycloalkyl, etc.; R10 = H, alkyl, (un)saturated cycloalkyl, etc.; R11 = alkyl, (un)saturated cycloalkyl, etc.; NR10R11 = (un)saturated heterocyclyl; R18 = H, alkyl, (un)saturated cycloalkyl, etc.] with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity (such as II [R1 = H, alkyl, Ph, CH2PH; R2 = NR4R5, (un)saturated (hetero)cycloalkyl, etc.; R3 = H, alkyl; R4, R5 = H, alkyl; or NR4R5 = (un)saturated heterocyclyl; A = (un)substituted (hetero)aryl; n = 0-4]), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament. Synthesis of amides I and sulfonamides such as II is described in examples. E.g., a multi-step synthesis of III.HCl, starting from 1-(tert-butoxycarbonyl)-4-piperidinone and Me anthranilate, was given. The amides I and sulfonamides such as II were tested against neuropeptide Y5 and 5-HT6 binding (data given for representative compds.).
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2005:136561 CAPLUS
DN 142:240311
TI Preparation of N-carbazolyl [(phenylamino)piperidinyl]acetamide derivatives as neuropeptide y5 ligands for the treatment of obesity
IN Torrens Jover, Antoni; Mas Prio, Josep; Dordal Zueras, Alberto; Fisas Escasany, Maria Angeles; Buschmann, Helmut Heinrich
PA Laboratorios del Esteve S. A., Spain
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005013990	A1	20050217	WO 2004-EP8517	20040729
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004262491	A1	20050217	AU 2004-262491	20040729
CA 2534101	A1	20050217	CA 2004-2534101	20040729
EP 1651220	A1	20060503	EP 2004-741322	20040729
EP 1651220	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829516	A	20060906	CN 2004-80021941	20040729
BR 2004012860	A	20061003	BR 2004-12860	20040729
JP 2007500169	T	20070111	JP 2006-521533	20040729
IN 2006DN00191	A	20070810	IN 2006-DN191	20060110
MX 2006001226	A	20060515	MX 2006-1226	20060130

	NO 2006000605	A	20060207	NO 2006-605	20060207
	US 20070105853	A1	20070510	US 2006-566399	20060926
PRAI	ES 2003-1813	A	20030730		
	WO 2004-EP8517	W	20040729		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:240311; MARPAT 142:240311

GI



I

AB Title compds. represented by the formula I [wherein m = 0-4; n = 0-3; p = 0-4; R1-R4 = independently H, halo, OR8, etc.; R5 = H, (cyclo)aliphatic radical; R6-R8 = independently H or prodrug-moiety; and physiol. acceptable salts or solvates thereof] were prepared as neuropeptide Y5 (NPY5) ligands (no data). For example, I (R1 = OH, R2-R4 = H, R5 = Me, m = 1, n = p = 0) was given in a multi-step synthesis starting from the reaction of 3-amino-9-methyl-9H-carbazole with chloroacetyl chloride. Thus, the title compds. are useful as NPY5 ligands in the treatment of obesity for humans or animals.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2005:136559 CAPLUS

DN 142:240321

TI Preparation of (phenylamino)piperidinylacetamides and related compounds as neuropeptide Y5 (NPY5) ligands for the treatment of obesity.

IN Torrens Jover, Antoni; Mas Prio, Josep; Fisas Escasany, Maria Angeles

PA Laboratorios del Esteve S.A., Spain

SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005013988	A1	20050217	WO 2004-EP8508	20040729
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	ES 2222833	A1	20050201	ES 2003-1813	20030730
	ES 2222833	B1	20060301		
	AU 2004262482	A1	20050217	AU 2004-262482	20040729

	CA 2534096	A1	20050217	CA 2004-2534096	20040729
	EP 1648458	A1	20060426	EP 2004-763608	20040729
	EP 1648458	B1	20061220		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	CN 1832745	A	20060913	CN 2004-80022263	20040729
	BR 2004013091	A	20061003	BR 2004-13091	20040729
	JP 2007500162	T	20070111	JP 2006-521526	20040729
	AT 348615	T	20070115	AT 2004-741322	20040729
	AT 348614	T	20070115	AT 2004-763608	20040729
	ES 2279400	T3	20070816	ES 2004-741322	20040729
	ES 2279419	T3	20070816	ES 2004-763608	20040729
	MX 2006001140	A	20060424	MX 2006-1140	20060127
	NO 2006000553	A	20060202	NO 2006-553	20060202
	US 20080119516	A1	20080522	US 2007-565979	20071105
PRAI	ES 2003-1813	A	20030730		
	EP 2004-741322	A	20040729		
	EP 2004-763608	A	20040729		
	WO 2004-EP8508	W	20040729		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 142:240321; MARPAT 142:240321

GI



I

AB Title compds. [I; R1-R4 = H, halo, NO2, cyano, (substituted) (unsatd.) aliphatyl, (hetero)cycloaliphatyl, aryl, heteroaryl, etc.; R5 = H, (substituted) (unsatd.) aliphatyl, cycloaliphatyl; R6-R9 = H, cyano, (substituted) (unsatd.) aliphatyl, (hetero)cycloaliphatyl, etc.; A = CHR18, CHR18CH2; B = (substituted) (unsatd.) aliphatyl, cycloaliphatyl, etc.; R10 = H, (substituted) (unsatd.) aliphatyl, (hetero)cycloaliphatyl, aryl, heteroaryl, etc.; R11 = (substituted) (unsatd.) aliphatyl, (hetero)cycloaliphatyl, aryl, heteroaryl, etc.; R10R11N = (substituted) (aromatic) heterocyclyl; R18 = H, (substituted) (unsatd.) aliphatyl, (hetero)cycloaliphatyl, aryl, heteroaryl, etc.], were prepared Thus, 1-(4-methyl-2-hydroxymethylphenylamino)piperidine dihydrochloride, 2-chloro-N-phenylacetamide, and K2CO3 were stirred together overnight in DMF to give 63% 4-[2-(2-hydroxymethyl-4-methylphenylamino)piperidin-1-yl]-N-phenylacetamide. Tested I showed NPY5 binding with IC50 = 40.1-80.9 nM. I are useful for the regulation of disorders of food ingestion, such as obesity, anorexia, cachexia, bulimia or type II diabetes, for the prophylaxis and/or treatment of disorders of the peripheral nervous system, disorders of the central nervous system, anxiety, depression, cognitive disorders, preferably memory disorders, cardiovascular diseases, pain, epilepsy, arthritis, hypertensive syndrome, inflammatory diseases, immune diseases and other NPY5 mediated disorders.

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 6

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

IT 844642-92-8P 844642-93-9P 844642-95-1P
845554-07-6P 845554-08-7P 845554-09-8P
845554-10-1P 845554-11-2P 845554-12-3P
845554-13-4P 845554-14-5P 845554-15-6P
845554-16-7P 845554-17-8P 845554-35-0P
845554-85-0P 845554-98-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of phenylaminopiperidinylacetamides and related
compds. as neuropeptide Y5 ligands for the treatment of obesity)

RN 844642-92-8 CAPLUS

CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[3-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 844642-93-9 CAPLUS

CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[4-hydroxy-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 844642-95-1 CAPLUS

CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-hydroxy-6-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845554-07-6 CAPLUS

CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845554-08-7 CAPLUS
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-09-8 CAPLUS
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-4-methylphenyl]amino]- (CA INDEX NAME)



RN 845554-10-1 CAPLUS
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[4-fluoro-2-(hydroxymethyl)phenyl]amino]- (CA INDEX NAME)



RN 845554-11-2 CAPLUS
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-6-methoxyphenyl]amino]- (CA INDEX NAME)



RN 845554-12-3 CAPLUS
CN 1-Piperidineacetamide, 4-[[4,5-difluoro-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-13-4 CAPLUS
CN 1-Piperidineacetamide, 4-[[3-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-14-5 CAPLUS
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-15-6 CAPLUS
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-16-7 CAPLUS
CN 1-Piperidineacetamide, 4-[[4-chloro-2-(hydroxymethyl)phenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-17-8 CAPLUS
CN 1-Piperidineacetamide, 4-[[2-(hydroxymethyl)-4-methylphenyl]amino]-N-(9-methyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-35-0 CAPLUS
CN 1-Piperidineacetamide, 4-[[4-bromo-2-(hydroxymethyl)phenyl]amino]-N-(9-ethyl-9H-carbazol-3-yl)- (CA INDEX NAME)



RN 845554-85-0 CAPLUS
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-3-methoxyphenyl]amino]- (CA INDEX NAME)



RN 845554-98-5 CAPLUS
CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]- (CA INDEX NAME)



IT 845525-15-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phenylaminopiperidinylacetamides and related compds. as neuropeptide Y5 ligands for the treatment of obesity)

RN 845525-15-7 CAPLUS

CN 1-Piperidineacetamide, N-(9-ethyl-9H-carbazol-3-yl)-4-[[2-(hydroxymethyl)-6-methylphenyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)